Quantcast
Last updated on April 18, 2014 at 13:58 EDT

Latest Baroreflex Stories

2014-01-07 08:29:32

Health Economic Analysis Published in the Journal of Hypertension MINNEAPOLIS, Jan. 7, 2014 /PRNewswire/ -- CVRx, Inc., a privately held medical device company, today announced findings from a health-economic analysis published in the Journal of Hypertension that indicates Barostim Therapy is a cost-effective treatment option for patients with drug resistant hypertension. Based on blood pressure reductions attained with Barostim therapy, the Markov model used for this analysis projected that...

2013-07-10 20:22:16

MINNEAPOLIS, July 10, 2013 /PRNewswire/ -- CVRx, Inc., a private medical device company, has completed a private equity financing totaling $29.6 million. CVRx plans to use the funding for the primary purposes of advancing its clinical trials and expanding its international commercial activities. New Enterprise Associates, Inc. (NEA) and Johnson & Johnson Development Corporation were the co-lead investors. Other participants in this round included existing investors BBT Fund L.P....

2013-04-29 08:26:42

Study will evaluate the second generation Barostim neo(TM) MINNEAPOLIS, April 29, 2013 /PRNewswire/ -- CVRx, Inc., a private medical device company, received Food and Drug Administration (FDA) investigational device exemption (IDE) approval, allowing the company to proceed with its hypertension study. The study is evaluating the safety and effectiveness of CVRx's Barostim neo(TM) in treating hypertension (high blood pressure). The prospective, randomized and controlled study will enroll...

2013-04-29 08:26:39

MINNEAPOLIS, April 29, 2013 /PRNewswire/ -- CVRx, Inc., a private medical device company, announced the first patient enrolled in the Barostim HOPE4HF clinical trial. The study is evaluating the effectiveness and safety of CVRx's Barostim neo in heart failure patients. Dr. Richard Abben, Director of Cardiac Intervention, with the Cardiovascular Institute of the South, in Houma, Louisiana is the Principal Investigator for the center. The prospective, randomized and controlled study will enroll...

2012-11-06 03:28:39

Spinal cord injury (SCI) can disrupt the body's sensitive signaling mechanisms that control blood pressure, breathing, and oxygen delivery to the heart and other organs during changes in body position. Cardiovascular (CV) disease is a leading cause of illness and death following SCI, and changes in baroreflex sensitivity–the body's ability to detect and respond to changes in blood pressure–may be predictive of a CV event. A comprehensive review article on baroreflex sensitivity...

Exercise Has Benefits, Even When It's Done In Space
2012-03-23 03:28:53

Astronauts have been taking part in short spaceflight missions since 1961. They have only recently begun to spend significantly longer times in space, with missions extending for months, since the days of the Russian Mir space station (1986-2001) and extended stays on the International Space Station (ISS; November 2000). Though earlier studies clearly showed that astronauts on these extended missions suffered serious deficits from lengthy times in a low-gravity environment, including...

2009-01-31 11:15:00

Huijing Xia, PhD, a postdoctoral research associate in the lab of Eric Lazartigues, PhD, Assistant Professor of Pharmacology at LSU Health Sciences Center New Orleans, is the lead author on a paper reporting that a recently identified enzyme in the brain plays a critically important role in the central regulation of blood pressure. The LSUHSC research team showed that Angiotensin-converting enzyme 2 (ACE2) helps preserve the function of a key spontaneous reflex involved in blood pressure...

2008-11-11 15:00:22

Clinical data on the use of the CVRx(R) Rheos(R) System show Rheos Therapy significantly improved heart structure and function in patients with high blood pressure. Peter W. de Leeuw, professor of medicine and hypertension at the University of Maastricht in The Netherlands, presented the data on November 11 (oral presentation #4426) at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans. In addition, data from a pre-clinical study indicate that, after receiving Rheos...

2008-09-23 09:01:09

Clinical data on the use of the CVRx(R) Rheos(R) System in treating early-stage heart failure patients shows Rheos Therapy significantly improved heart structure and function. John D. Bisognano, M.D, Ph.D., associate professor of medicine at the University of Rochester School of Medicine and Dentistry, New York, presented the data in a Sept. 22 poster session at the Heart Failure Society of America (HFSA) 12th Annual Scientific Meeting in Toronto. In heart failure patients, the heart becomes...

2008-07-30 09:01:27

CVRx, Inc., a private medical device company, has completed a fifth round of private equity financing totaling $84 million. The company has developed the Rheos(R) System, the only implantable device designed to control hypertension, or high blood pressure, a leading cause of heart and kidney disease, stroke and death. This device is intended to provide a new treatment option for the millions of people who cannot control their hypertension with medications. The Rheos System received CE Mark...